Skip to content

Screening for Fabry Disease in Renal Transplantation

Screening for Fabry Disease in Renal Transplantation

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03886714
Acronym
DEFYT
Enrollment
592
Registered
2019-03-22
Start date
2019-03-25
Completion date
2025-04-10
Last updated
2025-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fabry Disease, Nephropathy

Keywords

Fabry disease, Renal transplantation, Diabetic nephropathy, Focal Segmental Hyalinosis (FSH), Undetermined nephropathy

Brief summary

Single centre, prospective pilot study examining the relevance to screen for Fabry disease in a cohort of patients who have undergone renal transplantation for nephropathy of indeterminate cause, vascular nephropathy, diabetic nephropathy or secondary focal segmental hyalinosis with no established cause.

Detailed description

Exploration whether Fabry disease cases can be identified among patients who are followed at the Montpellier University Hospital after renal transplantation, with indeterminate cause of renal failure or diabetic nephropathy (due to its high frequency) or secondary focal segmental hyalinosis (FSH). At the population level, the identification of cases at the Montpellier centre could then justify to expand this screening to other French centres. The goal is to contribute to adapt current guidelines of renal failure assessment, by systematically including Fabry among the diagnostic tests. Whether all patients with renal failure are concerned, or only those with indeterminate cause, is an important question this study will address.

Interventions

Screening for the α-galactosidase (GAL) enzyme activity (men + women) and plasma Lyso globotriaosylsphingosine (GL3, women) for the diagnosis of Fabry disease.

DIAGNOSTIC_TESTScreen for α-galactosidase mutation

If necessary (positive for GAL), genetic confirmation tests for Fabry disease will be performed (men + women).

Sponsors

University Hospital, Montpellier
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Nephropathy of indeterminate cause, or secondary FSH or diabetic nephropathy * Patients with kidney transplanted * Patients still followed at the Montpellier University Hospital * Obtaining written informed consent * Age \> 18 years old, no upper age limit

Exclusion criteria

* N/A

Design outcomes

Primary

MeasureTime frameDescription
Number of Patients with Positive screen resultInclusion visitThe genetic analysis will be performed based on the biochemical results (low enzyme activity, raised lysoGL3)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026